Advanced search
Publication Cover
Clinical Interventions in Aging Volume 14, 2019 - Issue
Submit an article Journal homepage
105
Views
2
CrossRef citations to date
0
Altmetric
Case Report

Analysis of three-dimensional bone mineral density and bone strength measured by quantitative computed tomography following denosumab discontinuation in a patient with postmenopausal osteoporosis

Koki Tsuchiya1 Department of Orthopaedic Surgery, Showa University School of Medicine, Tokyo 142-8666, Japan
,
Koji Ishikawa1 Department of Orthopaedic Surgery, Showa University School of Medicine, Tokyo 142-8666, JapanCorrespondence[email protected]
,
Soji Tani1 Department of Orthopaedic Surgery, Showa University School of Medicine, Tokyo 142-8666, Japan
,
Yusuke Oshita2 Department of Orthopaedic Surgery, Yamanashi Red Cross Hospital, Yamanashi, Japan
,
Takuma Kuroda1 Department of Orthopaedic Surgery, Showa University School of Medicine, Tokyo 142-8666, Japan
,
Ryo Yamamura1 Department of Orthopaedic Surgery, Showa University School of Medicine, Tokyo 142-8666, Japan
,
Haruka Emori1 Department of Orthopaedic Surgery, Showa University School of Medicine, Tokyo 142-8666, Japan
,
Hiroshi Maruyama1 Department of Orthopaedic Surgery, Showa University School of Medicine, Tokyo 142-8666, Japan
,
Akira Matsuoka1 Department of Orthopaedic Surgery, Showa University School of Medicine, Tokyo 142-8666, Japan
,
Yoshifumi Kudo1 Department of Orthopaedic Surgery, Showa University School of Medicine, Tokyo 142-8666, Japan
,
Toshiyuki Shirahata1 Department of Orthopaedic Surgery, Showa University School of Medicine, Tokyo 142-8666, Japan
,
Tomoaki Toyone1 Department of Orthopaedic Surgery, Showa University School of Medicine, Tokyo 142-8666, Japan
,
Takashi Nagai1 Department of Orthopaedic Surgery, Showa University School of Medicine, Tokyo 142-8666, Japan
&
Katsunori Inagaki1 Department of Orthopaedic Surgery, Showa University School of Medicine, Tokyo 142-8666, Japan
 show all
Pages 1445-1450 | Published online: 07 Aug 2019

References

  • Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513–523. doi:10.1016/S2213-8587(17)30138-928546097
  • Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O. Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res. 2017;32(6):1291–1296. doi:10.1002/jbmr.311028240371
  • Faienza MF, Chiarito M, D’amato G, et al. Monoclonal antibodies for treating osteoporosis. Expert Opin Biol Ther. 2018;18(2):149–157. doi:10.1080/14712598.2018.1401607
  • Karlsson L, Lundkvist J, Psachoulia E, Intorcia M, Ström O. Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis. Osteoporos Int. 2015;26(10):2401–2411. doi:10.1007/s00198-015-3253-426282229
  • Ishikawa K, Nagai T, Tsuchiya K, et al. High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis. Clin Inter Aging. 2018;13:1929–1934. doi:10.2147/CIA.S180614
  • Popp AW, Zysset PK, Lippuner K. Rebound-associated vertebral fractures after discontinuation of denosumab—from clinic and biomechanics. Osteoporosis Int. 2016;27(5):1917–1921. doi:10.1007/s00198-015-3458-6
  • Niimi R, Kono T, Nishihara A, Hasegawa M, Kono T, Sudo A. Rebound-associated vertebral fractures after discontinuation of denosumab for the treatment of maxillitis. Osteoporosis Int. 2018;29(3):769–772. doi:10.1007/s00198-017-4334-3
  • Aubry-Rozier B, Gonzalez-Rodriguez E, Stoll D, Lamy O. Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Osteoporosis Int. 2016;27(5):1917–1921. doi:10.1007/s00198-015-3380-y
  • Kanis JA; on behalf of the World Health Organisation Scientific Group. Assessment of Osteoporosis at the Primary Health Care Level. WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield; 2007 Available from: http://www.shef.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf. Accessed July 29. 2019.
  • Ito M, Wakao N, Hida T, et al. Analysis of hip geometry by clinical CT for the assessment of hip fracture risk in elderly Japanese women. Bone. 2010;46(2):453–457. doi:10.1016/j.bone.2009.08.05919735752
  • Ito M, Nakamura T, Fukunaga M, Shiraki M, Matsumoto T. Effect of eldecalcitol, an active vitamin D analog, on hip structure and biomechanical properties: 3D assessment by clinical CT. Bone. 2011;49(2):328–334. doi:10.1016/j.bone.2011.05.00221605716
  • Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011;96(4):972–980. doi:10.1210/jc.2010-150221289258
  • Eriksen EF. Cellular mechanisms of bone remodeling. Rev Endocr Metab Discord. 2010;11(4):219–227. doi:10.1007/s11154-010-9153-1
  • Diederichs G, Engelken F, Marshall LM, et al. Diffuse idiopathic skeletal hyperostosis (DISH): relation to vertebral fractures and bone density. Osteoporos Int. 2011;22(6):1789–1797. doi:10.1007/s00198-010-1409-920882271
  • Ishikawa K, Toyone T, Shirahata T, et al. A novel method for the prediction of the pedicle screw stability: regional bone mineral density around the screw. Clin Spine Surg. 2018;31(9):473–480. doi:10.1097/BSD.0000000000000703
  • Ishikawa K, Fukui T, Nagai T, et al. Type 1 diabetes patients have lower strength in femoral bone determined by quantitative computed tomography: a cross-sectional study. J Diabetes Investig. 2015;6(6):726–733. doi:10.1111/jdi.12372
  • McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM. Observations following discontinuation of long-term denosumab therapy. Osteoporosis Int. 2017;28(5):1723–1732. doi:10.1007/s00198-017-3919-1
  • Uebelhart B, Rizzoli R, Ferrari SL. Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates. Osteoporosis Int. 2017;28(9):2701–2705. doi:10.1007/s00198-017-4080-6
  • Cummings SR, Ferrari S, Eastell R. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo‐controlled FREEDOM trial and its extension. J Bone Miner Res. 2018;33(2):188–189. doi:10.1002/jbmr.333729232486

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.